Cargando…
IL‐17 serum level in patients with chronic mucocutaneous candidiasis disease
BACKGROUND: Chronic mucocutaneous candidiasis (CMC) is defined by recurrent or persistent superficial infections involving nails, skin, and/or oral and genital mucosae. IL‐17 promotes the recruitment, chemotaxis, and expansion of neutrophils and acts directly on keratinocytes and epithelial cells, d...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306849/ https://www.ncbi.nlm.nih.gov/pubmed/35080300 http://dx.doi.org/10.1111/pai.13636 |
_version_ | 1784752632920801280 |
---|---|
author | Chimenz, Roberto Tropeano, Angelo Chirico, Valeria Ceravolo, Giorgia Salpietro, Carmelo Cuppari, Caterina |
author_facet | Chimenz, Roberto Tropeano, Angelo Chirico, Valeria Ceravolo, Giorgia Salpietro, Carmelo Cuppari, Caterina |
author_sort | Chimenz, Roberto |
collection | PubMed |
description | BACKGROUND: Chronic mucocutaneous candidiasis (CMC) is defined by recurrent or persistent superficial infections involving nails, skin, and/or oral and genital mucosae. IL‐17 promotes the recruitment, chemotaxis, and expansion of neutrophils and acts directly on keratinocytes and epithelial cells, driving the production of antimicrobial peptides, essential for the immune response against Candida. AIM: To evaluate the serum level of IL‐17 in a family affected by CMC restricted to the nails of the hands and feet. METHODS: Serum IL‐17 was assayed on 16 patients (aged 21 ± 3.1 years) suffering from persistent onychomycosis caused by Candida and 18 healthy controls (aged 19 ± 2.7 years). Comparisons between groups were performed by Student's unpaired t‐test. The level of significance was set at 0.05. RESULTS: The mean serum IL‐17 level in patients was 74 ± 1.42 pg/ml, whereas the control group showed a significantly lower level of 25.6 ± 6.7 pg/ml (p < 0.05). CONCLUSIONS: We showed a potential defect in the IL‐17 signaling pathway in a family affected by CMC restricted to the nails of the hands and feet. Further research is needed to clarify the immunological mechanisms and the genetic etiology at the basis of the unusual clinical presentation in this family. |
format | Online Article Text |
id | pubmed-9306849 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93068492022-07-28 IL‐17 serum level in patients with chronic mucocutaneous candidiasis disease Chimenz, Roberto Tropeano, Angelo Chirico, Valeria Ceravolo, Giorgia Salpietro, Carmelo Cuppari, Caterina Pediatr Allergy Immunol Special Issue: 2021 Update From The Italian Society Of Pediatric Allergy And Immunology BACKGROUND: Chronic mucocutaneous candidiasis (CMC) is defined by recurrent or persistent superficial infections involving nails, skin, and/or oral and genital mucosae. IL‐17 promotes the recruitment, chemotaxis, and expansion of neutrophils and acts directly on keratinocytes and epithelial cells, driving the production of antimicrobial peptides, essential for the immune response against Candida. AIM: To evaluate the serum level of IL‐17 in a family affected by CMC restricted to the nails of the hands and feet. METHODS: Serum IL‐17 was assayed on 16 patients (aged 21 ± 3.1 years) suffering from persistent onychomycosis caused by Candida and 18 healthy controls (aged 19 ± 2.7 years). Comparisons between groups were performed by Student's unpaired t‐test. The level of significance was set at 0.05. RESULTS: The mean serum IL‐17 level in patients was 74 ± 1.42 pg/ml, whereas the control group showed a significantly lower level of 25.6 ± 6.7 pg/ml (p < 0.05). CONCLUSIONS: We showed a potential defect in the IL‐17 signaling pathway in a family affected by CMC restricted to the nails of the hands and feet. Further research is needed to clarify the immunological mechanisms and the genetic etiology at the basis of the unusual clinical presentation in this family. John Wiley and Sons Inc. 2022-01-25 2022-01 /pmc/articles/PMC9306849/ /pubmed/35080300 http://dx.doi.org/10.1111/pai.13636 Text en © 2022 The Authors. Pediatric Allergy and Immunology published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Special Issue: 2021 Update From The Italian Society Of Pediatric Allergy And Immunology Chimenz, Roberto Tropeano, Angelo Chirico, Valeria Ceravolo, Giorgia Salpietro, Carmelo Cuppari, Caterina IL‐17 serum level in patients with chronic mucocutaneous candidiasis disease |
title | IL‐17 serum level in patients with chronic mucocutaneous candidiasis disease
|
title_full | IL‐17 serum level in patients with chronic mucocutaneous candidiasis disease
|
title_fullStr | IL‐17 serum level in patients with chronic mucocutaneous candidiasis disease
|
title_full_unstemmed | IL‐17 serum level in patients with chronic mucocutaneous candidiasis disease
|
title_short | IL‐17 serum level in patients with chronic mucocutaneous candidiasis disease
|
title_sort | il‐17 serum level in patients with chronic mucocutaneous candidiasis disease |
topic | Special Issue: 2021 Update From The Italian Society Of Pediatric Allergy And Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306849/ https://www.ncbi.nlm.nih.gov/pubmed/35080300 http://dx.doi.org/10.1111/pai.13636 |
work_keys_str_mv | AT chimenzroberto il17serumlevelinpatientswithchronicmucocutaneouscandidiasisdisease AT tropeanoangelo il17serumlevelinpatientswithchronicmucocutaneouscandidiasisdisease AT chiricovaleria il17serumlevelinpatientswithchronicmucocutaneouscandidiasisdisease AT ceravologiorgia il17serumlevelinpatientswithchronicmucocutaneouscandidiasisdisease AT salpietrocarmelo il17serumlevelinpatientswithchronicmucocutaneouscandidiasisdisease AT cupparicaterina il17serumlevelinpatientswithchronicmucocutaneouscandidiasisdisease |